FDAnews Drug Daily Bulletin

Mylan Pharmaceuticals has confirmed that its proposed $4 billion acquisition of brand firm King Pharmaceuticals is in jeopardy.

The Institute of Medicine has issued a report recommending that dietary supplements be subject to much more stringent rules governing safety and effectiveness -- much in the same way prescription drugs are regulated.

The FDA's highly anticipated advisory committee meeting addressing the safety of Cox-2 inhibitors has been scheduled for Feb. 16-18.

Bristol-Myers Squibb (BMS) is selling its U.S. and Canadian consumer medicines business, the company recently confirmed.

Amid a national debate over how to reform scientific research and boost innovation, a leading voice for French biotechnology has been meeting with government ministers to help close France's biotech gap with the U.S. and Britain.

Southern Research Institute today formally announced that it has launched a new for-profit company, Brookwood Pharmaceuticals, Inc., spinning out the Institute's 30-year old in-house drug delivery group which focuses on the development of time-release formulations for pharmaceuticals delivery.

KV Pharmaceutical has additional borrowing capacity with its lenders after amending its loan agreements late last month, it said in a regulatory filing.

AIN Pharmaciez has decided to acquire Rejoice and Rejoice Pharmacy by mid-March to April.

SA's medicine manufacturers have indicated that they would continue to sell medicines at the reduced prices stipulated by the disputed medicine-pricing regulations, until the Constitutional Court has given direction on the matter.

Biobase, the German specialist in commercial biological databases, announced today the successful acquisition of Proteome Inc., a wholly-owned subsidiary of Incyte Corporation.

Shire Pharmaceuticals Group, based in Britain, said it licensed its HIV compound SPD754 to Avexa Ltd., an Australian specialty anti-infectives company.

Adenosine Therapeutics has signed a worldwide collaboration and option agreement with Ortho-McNeil Pharmaceutical to further develop A2B adenosine receptor antagonist compounds for the potential treatment of Type II diabetes, asthma and other disorders.

Neoprobe has formed a new subsidiary to develop technology that has shown promise treating diseases such as cancer and HIV.